Clinical trials: Depressive State
Bipolar I Depression
A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression
The study evaluates the efficacy and safety of lurasidone compared with placebo in treating Bipolar I Depression.
- Trial name
- NCT04383691
- Testing
- Lurasidone HCl
- Where
- 26 sites in China
- Volunteers
- 124 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Erectile Dysfunction, Depression
Depression Related Improvement With Vardenafil for Erectile Response
The study will last three months. During the first month of treatment the subject will receive either 10 mg vardenafil or placebo.
- Trial name
- DRIVER (NCT00661219)
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 280 people
- Sponsor
- Bayer
Anxiety, Microbiome
Microbiome, Anxiety and Cognitive Orientation Study
Mounting evidence shows that the gut microbiome plays an important role in communication within the gut-brain axis. However, the relationship between gut microbiota and their influence on anxiety is still not fully understood.
- Conditions
- Anxiety, Microbiome, Mood Disorders, Neurodegeneration
- Trial name
- MACO (NCT05388630)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Endominance
Depression
Digital Therapeutic vs Educational App for Depression Among Adolescents
The primary aim of this study is to investigate the difference in depression symptoms at 4-weeks across two types of programs for addressing depressive symptoms, including Woebot (WB002) and Digital Education (ED002).
- Trial name
- NCT05486611
- Testing
- W-GenZD Mobile Application, Digital Education Application (W-EdZD)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Woebot Health
Major Depressive Disorder
A Study for Participants With Major Depression
This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.
- Trial name
- NCT00420004
- Testing
- LY2216684, Escitalopram
- Where
- 7 sites in United States, Romania
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Suicide, Suicidal
CAMPUS Expanded "Classification and Assessment of Mental Health Performance Using Semantics Expanded"
Open enrollment study to collect data for the optimization of machine learning models for use in an app for the early detection of mental health and suicidal risk.
- Conditions
- Suicide, Suicidal, Suicide, Attempted, Suicidal Ideation
- Trial name
- CAMPUS-E (NCT04493736)
- Testing
- MHSAFE app recording
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Clarigent Health
Major Depressive Disorder
Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)
To confirm the safety and efficacy of the NCP System in treating patients in a nmajor depressive episode.
- Trial name
- NCT00533832
- Testing
- vagus nerve stimulation (VNS)
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Cyberonics, Inc.
Depression, Anxiety
Clairity in a University Mental Health Clinic
This is a clinical trial to evaluate the effectiveness of the Clairity tool within the university setting for students who are being seen by a mental health provider.
- Conditions
- Depression, Anxiety, Suicide, Mental Health Issue
- Trial name
- FECU (NCT05513963)
- Testing
- Clairity
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Clarigent Health
Generalized Anxiety Disorder
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.
- Trial name
- NCT06051721
- Testing
- CYB004, Psychotherapy
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Cybin IRL Limited
Depression
To Demonstrate the Relative Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets
To demonstrate the relative bioequivalency of Cord's 100 mg Desipramine HCl tablets to Merrell Dow's 100 mg Norpramin tablets.
- Trial name
- NCT00913809
- Testing
- Desipramine HCL 100 mg Tablets Cord Laboratories, Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD).
- Trial name
- NCT06357832
- Testing
- Brainsway Deep TMS System
- Where
- 9 sites in United States, India and 1 more
- Volunteers
- 104 people
- Sponsor
- Brainsway
Bipolar Depression
A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
The purpose of this first in human (FIH) study is to investigate the safety, tolerability, pharmacokinetics ( how the body handles the drug) and pharmacodynamics (how the drug affects the body) of PF-04455242-01 in healthy adult…
- Trial name
- NCT00938301
- Testing
- PF-04455242
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia
Four Dimensions in Schizophrenia
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 4 assessment will be carried out , in months 0, 1, 3 and 6.
- Trial name
- 4D (NCT00782899)
- Where
- 65 sites in Spain
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Bipolar Disorder
BHV-7000 Acute Treatment of Bipolar Mania
The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
- Trial name
- NCT06419582
- Testing
- BHV-7000
- Where
- 32 sites in United States
- Volunteers
- 274 people
- Sponsor
- Biohaven Therapeutics Ltd.
Psychotic Disorders, Schizophrenia
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after…
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT02087579
- Testing
- Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation
- Where
- 24 sites in United States, Argentina and 5 more
- Volunteers
- 305 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Treatment-Resistant
Epidemiology of Treatment Resistant Depression in Taiwan
The purpose of this study is to assess the epidemiology of Treatment Resistant Depression (TRD) in the nationally insured population in Taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.
- Trial name
- NCT02691520
- Volunteers
- 8,356 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Insomnia
A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00435279
- Testing
- Eszopiclone, Venlafaxine
- Where
- 69 sites in Austria, Croatia and 8 more
- Volunteers
- 678 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depressive Symptoms Mild to Moderate in Severity
A Pilot Study of Synbiotics in Adults With Depressive Symptoms
This study aims to explore the efficacy and safety of a synbiotic formula (MQU10) in improving mood and well-being in adults with mild to moderate depressive symptoms.
- Trial name
- NCT06905223
- Testing
- MQU10
- Where
- 2 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- GenieBiome Limited
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an…
- Trial name
- SPARC-TMS (NCT07227103)
- Testing
- Neuronavigated robotic-enabled TMS, NRX-101
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroRx, Inc.
Depressive Disorder
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo…
- Trial name
- NCT00336713
- Testing
- Saredutant (SR48968C)
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- Sanofi